CY1105803T1 - COMPOSITION OF PEPILAMVANOUS CAMPTOTHEKIN AND A PYRIMIDINE DERIVATIVE FOR THE TREATMENT OF CANCER - Google Patents

COMPOSITION OF PEPILAMVANOUS CAMPTOTHEKIN AND A PYRIMIDINE DERIVATIVE FOR THE TREATMENT OF CANCER

Info

Publication number
CY1105803T1
CY1105803T1 CY20061101699T CY061101699T CY1105803T1 CY 1105803 T1 CY1105803 T1 CY 1105803T1 CY 20061101699 T CY20061101699 T CY 20061101699T CY 061101699 T CY061101699 T CY 061101699T CY 1105803 T1 CY1105803 T1 CY 1105803T1
Authority
CY
Cyprus
Prior art keywords
cancer
treatment
pepilamvanous
camptothekin
composition
Prior art date
Application number
CY20061101699T
Other languages
Greek (el)
Inventor
Marie-Christine Bissery
Original Assignee
Pfizer Enterpises Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Enterpises Sarl filed Critical Pfizer Enterpises Sarl
Publication of CY1105803T1 publication Critical patent/CY1105803T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Περιγράφονται θεραπευτικές φαρμακευτικές συνθέσεις που περιλαμβάνουν παράγωγο πυριμιδίνης σε συνδυασμό με καμπτοθεκίνη ή ένα παράγωγο καμπτοθεκίνης για τη θεραπεία καρκίνου. Σε μια πραγματοποίηση, το παράγωγο πυριμιδίνης είναι καπεσιταμπίνη και το παράγωγο καμπτοθεκίνης είναι CPT-11.Therapeutic pharmaceutical compositions comprising a pyrimidine derivative in combination with camptothecin or a camptothecin derivative for the treatment of cancer are described. In one embodiment, the pyrimidine derivative is capecitabine and the camptothecin derivative is CPT-11.

CY20061101699T 2000-02-28 2006-11-24 COMPOSITION OF PEPILAMVANOUS CAMPTOTHEKIN AND A PYRIMIDINE DERIVATIVE FOR THE TREATMENT OF CANCER CY1105803T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18537800P 2000-02-28 2000-02-28
US20893800P 2000-06-05 2000-06-05
PCT/EP2001/002723 WO2001062235A2 (en) 2000-02-28 2001-02-26 A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer

Publications (1)

Publication Number Publication Date
CY1105803T1 true CY1105803T1 (en) 2011-02-02

Family

ID=26881090

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101699T CY1105803T1 (en) 2000-02-28 2006-11-24 COMPOSITION OF PEPILAMVANOUS CAMPTOTHEKIN AND A PYRIMIDINE DERIVATIVE FOR THE TREATMENT OF CANCER

Country Status (28)

Country Link
US (3) US6503889B2 (en)
EP (1) EP1278518B1 (en)
JP (1) JP2003523980A (en)
KR (1) KR100717916B1 (en)
CN (1) CN1424912A (en)
AT (1) ATE344670T1 (en)
AU (1) AU785467B2 (en)
BR (1) BR0108728A (en)
CA (1) CA2401191C (en)
CY (1) CY1105803T1 (en)
CZ (1) CZ298259B6 (en)
DE (1) DE60124387T2 (en)
DK (1) DK1278518T3 (en)
EA (1) EA005619B1 (en)
EE (1) EE200200471A (en)
ES (1) ES2273841T3 (en)
HR (1) HRP20020658A2 (en)
HU (1) HUP0300848A3 (en)
IL (1) IL150953A0 (en)
MX (1) MXPA02008355A (en)
NO (1) NO324772B1 (en)
NZ (1) NZ520593A (en)
PL (1) PL363110A1 (en)
PT (1) PT1278518E (en)
SK (1) SK12242002A3 (en)
TW (1) TWI239841B (en)
WO (1) WO2001062235A2 (en)
YU (1) YU64602A (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20030092608A1 (en) * 2001-08-21 2003-05-15 Takayuki Kawaguchi Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
US7026301B2 (en) * 2002-10-17 2006-04-11 New York University Method of orally treating inflammatory skin conditions with prodrugs of 5-fluorouracil
ITMI20030317A1 (en) * 2003-02-21 2004-08-22 Pharmacia Italia Spa COMBINED THERAPY INCLUDING AN INDOLOPIRROLOCARBAZOLO DERIVATIVE AND ANOTHER ANTI-CANCER AGENT.
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
RS50692B (en) * 2003-11-13 2010-06-30 Pharma Mar S.A.U. Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
CA2563502A1 (en) 2004-04-09 2005-10-20 Chugai Seiyaku Kabushiki Kaisha Novel water-soluble prodrug
JP2008501007A (en) * 2004-05-28 2008-01-17 ファイザー・プロダクツ・インク Methods for treating abnormal cell proliferation
KR20070034536A (en) * 2004-06-04 2007-03-28 스미스클라인 비이참 (코르크) 리미티드 Cancer treatment method
WO2005117980A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
DE112006000873T5 (en) * 2005-04-12 2008-03-06 Elan Pharma International Ltd. Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer
BRPI0613796A2 (en) * 2005-06-07 2011-02-15 Univ Yale pharmaceutical compositions and their uses, and methods of treating cancer and other pathological conditions or conditions by the use of clevudine (lfmau) and telbivudine (ldt)
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
WO2010129545A2 (en) 2009-05-04 2010-11-11 Psivida Us, Inc. Porous silicon drug-eluting particles
HUE027831T2 (en) * 2010-03-12 2016-11-28 Genzyme Corp Combination therapy for treating breast cancer
CN104622790A (en) 2010-11-01 2015-05-20 普西维达公司 Bioerodible silicon-based devices for delivery of therapeutic agents
WO2014151381A1 (en) 2013-03-15 2014-09-25 Psivida Us, Inc. Bioerodible silicon-based compositions for delivery of therapeutic agents

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57116015A (en) 1981-01-09 1982-07-19 Yakult Honsha Co Ltd Antitumor agent
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
JPS57116074A (en) 1981-01-09 1982-07-19 Yakult Honsha Co Ltd Novel camptothecin derivative and its preparation
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS58154582A (en) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd Novel camptothecin derivative and its preparation
JPS595188A (en) 1982-06-30 1984-01-12 Yakult Honsha Co Ltd Production of 10-hydroxycamptothecin
JPS5951289A (en) 1982-09-17 1984-03-24 Yakult Honsha Co Ltd Novel 9-substituted camptothecin derivative
JPS6019790A (en) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd Novel camptothecin derivative
US4981968A (en) 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
CA1332413C (en) 1987-06-25 1994-10-11 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0615547B2 (en) 1988-01-20 1994-03-02 株式会社ヤクルト本社 Novel camptothecin derivative
JP2524804B2 (en) 1988-03-29 1996-08-14 株式会社ヤクルト本社 Novel camptothecin derivative and method for producing the same
JP2524803B2 (en) 1988-03-29 1996-08-14 株式会社ヤクルト本社 Novel camptothecin derivative and method for producing the same
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
DE69209969T2 (en) 1991-10-29 1996-09-12 Glaxo Wellcome Inc Water soluble camptothecin derivatives
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
GB9510716D0 (en) 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
US5670500A (en) 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
US5663177A (en) 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
DK0835258T3 (en) 1995-06-21 2003-02-03 Sod Conseils Rech Applic New Camptothecin Analogs, Methods of Preparation thereof, Their Use as Medicines and Pharmaceutical Preparations Containing These
IL143920A0 (en) * 1998-12-31 2002-04-21 Sugen Inc 3-heteroarylidenyl-2-indolinone derivatives and pharmaceutical compositions containing the same
US6191119B1 (en) 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds

Also Published As

Publication number Publication date
CZ298259B6 (en) 2007-08-08
HUP0300848A3 (en) 2005-03-29
PT1278518E (en) 2007-01-31
US20020068743A1 (en) 2002-06-06
ATE344670T1 (en) 2006-11-15
HUP0300848A2 (en) 2003-08-28
HRP20020658A2 (en) 2004-12-31
NZ520593A (en) 2004-10-29
CA2401191A1 (en) 2001-08-30
NO20024076D0 (en) 2002-08-27
NO20024076L (en) 2002-08-27
CZ20022892A3 (en) 2002-11-13
US6503889B2 (en) 2003-01-07
NO324772B1 (en) 2007-12-10
KR20020082856A (en) 2002-10-31
WO2001062235A2 (en) 2001-08-30
ES2273841T3 (en) 2007-05-16
DE60124387T2 (en) 2007-10-11
US20030096789A1 (en) 2003-05-22
AU6011101A (en) 2001-09-03
MXPA02008355A (en) 2002-12-13
IL150953A0 (en) 2003-02-12
US6664242B2 (en) 2003-12-16
EA005619B1 (en) 2005-04-28
PL363110A1 (en) 2004-11-15
CA2401191C (en) 2006-05-02
SK12242002A3 (en) 2003-02-04
EP1278518B1 (en) 2006-11-08
YU64602A (en) 2005-06-10
BR0108728A (en) 2003-12-30
EE200200471A (en) 2003-12-15
CN1424912A (en) 2003-06-18
DK1278518T3 (en) 2007-01-15
US20020091132A1 (en) 2002-07-11
EP1278518A2 (en) 2003-01-29
AU785467B2 (en) 2007-07-26
EA200200922A1 (en) 2003-04-24
KR100717916B1 (en) 2007-05-11
DE60124387D1 (en) 2006-12-21
JP2003523980A (en) 2003-08-12
TWI239841B (en) 2005-09-21
WO2001062235A3 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
CY1105803T1 (en) COMPOSITION OF PEPILAMVANOUS CAMPTOTHEKIN AND A PYRIMIDINE DERIVATIVE FOR THE TREATMENT OF CANCER
CY1118480T1 (en) TOY UK-2A PRODUCERS
CY1116103T1 (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
TR200200717T2 (en) Therapeutic quinazoline derivatives.
CY1108339T1 (en) SPIRO DERIVATIVES (2H-1-BENZOPYRAN-2,4IP-PIPERIDINE) AS GLYCINE TRANSPORT INHIBITORS
CY1108408T1 (en) DIAZEPINOIDOLINE PRODUCTS AS MOVING SUSPENSIONS
CY1114708T1 (en) PYRAZOLO-KINAZOLINE PRODUCERS, PROCEDURE FOR THEIR PREPARATION AND THEIR USE AS MICROSOFT
ATE411022T1 (en) PYRIDYLPYRROLE DERIVATIVES AS EFFECTIVE KINASE INHIBITORS
CY1110914T1 (en) TWIN-CYCLOTS ACTIVE AS CHINESE RESTRICTIONS, PROCESSING FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM
CY1117217T1 (en) COMPOSITION AND ANTI-VISUAL ACTIVITY OF SUBSTITUTED AZAIDOLOOXOXIC PRODUCERS OF Piperazine
PT1017675E (en) CAMPOTECIN DERIVATIVES HIGHLY LIPOFILOS
NO20035699D0 (en) Pharmaceutical compositions comprising low-solubility and / or acid-sensitive drugs and neutralized acidic polymers
CY1108254T1 (en) COMPOUNDS THAT INFLUENCE Glycokinase
ATE236147T1 (en) DERIVATIVES OF FLAVONES, XANTHONES AND CUMARINES
CY1114422T1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES MEN'S FOR THERAPEUTIC TREATMENT
CY1106449T1 (en) IMPROVED METHOD FOR ERADICATION OF HELICOBACTER PYLORI
DE60142913D1 (en) DRUG SOLUTIONS CONTAIN MODAFINIL COMPOUNDS
CY1108890T1 (en) 7-IMINO ANTI-ACTIVE CAMPTOTHEKIN PRODUCERS
DE60229287D1 (en) Pharmaceutical preparation for oral use of heparin and its derivatives
DE60026046D1 (en) 5-HYDROXYSAPOGENES DERIVATIVES WITH ACTIVITY AGAINST DEMENTIA
NO20031410D0 (en) Antitumor therapy including distamycin derivatives
NO20054723L (en) Treatment of proliferative diseases with epophilone derivatives and radiation
HUP0302629A2 (en) Pharmaceutical compositions comprising a combination camptothecin and a stilbene derivative for the treatment of cancer
UY26498A1 (en) SUBSTITUTED PYRROLES
CY1115806T1 (en) PRODUCTS OF CYCLIC ESTE UK-2A USEFUL IN PREVENTION OR TREATMENT OF MYTHOLOGICAL DISEASES